

McNEIL CONSUMER FORT WASHI



N,

Pege \_\_\_

A. Patient in				C. Suspect med	iontic			
Petient identifier	2. Age at time of event:	3. Sex	4. Weight	1. Name (give labeled stre	noth & n	II(S) ntr/labeler if ke		
	or 12 mo	()female	lbs	1		mmadeler, II KA	own;	
017-16468216	Date	~	or	#1 Infants' TYLENOL	urops			
In confidence	of birth:	(X)male	10 kgs	1				
B. Adverse ev	ent or product probl	em		2. Dose, frequency & route	e used	3. Therapy da	etes (if	unknown, give duration
1. X Adverse event and/or Product problem (e.g., defects/malfunctions)				from/to for best estimatel  from/to for best estimatel  from/to for best estimatel  from/to for best estimatel  from/to for best estimatel				
2. Outcomes attribute (check all that appli	d to adverse event			#2	<u>, po</u>	#2	36 ho	ours; 9 doses
		bility		4. Diagnosis for use (indica	tion)	1*2	15 E.	rent sheted after use
( ) death ( ) congenital enomaly				#1 unknown			stopped or dose reduced	
( ) life-threaten	( ) (44)	ired intervention to nament impairment/o	prevent					(Y) You ( ) H- ( )
(X) hospitalizati	or prototyped		an Hedo	#2				(X) Yes ( ) No ( )
3. Date of event	(X) other	r: recovered		6. Lot # (if known)	7. Exp.	date (if known)	102	( ) Yes ( ) No ( )
4/24/93	4. Date of this repo			#1 Unknown	#1	Unknown	<u> </u>	ent reappeared after
(mo/day/yr)	(mo/dey/yr)	02/11/98		12	#2		reio	ntroduction
5. Describe event or pr	meldo			0.400.4	<u> </u>		#1 C	) Yes ( ) No (X) N
Case report receive	ested from			9. NDC # - for product probl	lems only	(if known)	l —	· · · · / · · · · / · / · / · · ·
Nonprescription	ested from in prepa	ration for th	e FDA	• •		ı	#2 (	) Yes ( ) No ( ) N
Nonprescription Drugs Advisory Committee Meeting on Dosing/Labeling of Pediatric Analgesics/Antipyretics held				10. Concomitant medical products and therapy dates lexified treatment of any				
9/18/97. Report	indicates a 12 month old	male use sive	eta - 5	unknown		F,	JONOIL	nee treatment of event)
(500 mg) of aceta	minophen drops every 3-4	hours as sive	ח אשר					
Patient received	9 teaspoonfuls (45 ml or	4.5 cm) cure	gea.					
hours (OVERDOSE).	According to report, far	mily had min		0 011				
stood the dischar	ge instructions. Patient	Dresented to		G. All manufacture	ers			
stood the discharge instructions. Patient presented to emergency room asymptomatic, however, LIVER FUNCTION TEST				. Contact office - name/addr			vices)	2. Phone number
ABNORMAL. Patient's PT=15.7 and protein was found in urine				McNeil Consumer Products Company 215-233-7820				
(ALBUMINURIA). Therapy was initiated with n-acetylcysteine				Medical Affairs				3. Report source
(NAC). Patient's LFT's continued to increase and PT rose to				7050 Camp Hill Road				(check all that apply
8 (PROTHROMBIN INCREASED). Patient transfered to 2nd				Ft. Washington, PA 19034				( ) foreign
hospital. LFT's pe	aked two days following	admission.	1					( ) study
Bilirubin within r	normal limits throughout	hospitalizatio	on.					( ) literature
Patient received e	ntire course of NAC and	was discharged						( ) consumer
nome in good condi	tion.	320		Date received by manufactur				health
				(mo/day/yr) 02/03/98	- 1			(x) professional
						DA # 17-552		( ) user facility
			<b>1</b> °.	if IND, protocol #	J	ID#		company
	ory data, including dates				- 1	.A.# m.1029	. 1	( ) représentative
n ER: AST=700, LD	H=799, Alk Phos=214, PT=1	5.7; protein	7.	Type of report	-  °′	n-1938 ( ) 1	res	( ) distributor
ound in urine; ac	etaminophen level=25 mcg/	ml; PT rose t	. 1	(check all that apply)		TC oduct (Y) )	,	( ) other:
8; Two days follo	wing admission: AST=13,07	4, ALT=11,790	1	) 5-day (X) 15-day		oduct (χ) γ	es	
see Sect B7)				) 10-day ( ) periodic	8. Adv	verse event tem	n(s)	
			1 6	X) initial ( ) follow-up #		ERDOSE		MED SIMILA COM
			L		ı			VER FUNC ABNO
			9.	Mfr. report number	7 ~	OTHROMBIN IN	U AL	BUMINURIA
Other relevant history,	including preexisting medical cor	rditions (s. s. s.	0	931690A				
	ng and alcohol use, hepatic/rena	dysfunction, etc	ryies.	Initial reporter				
nknown				Verme, address & phone #				
		•	-					
ect B6 con't: bili	rubin within normal limit	s throughout						
spitalization; la	st recorded AST=390 & ALT	=3867						
			<b>.</b>					
			2. H	ealth professional?  3 Occu		<del></del>		



7.

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

Initial reporter elso sent report to FDA

(X) Yes ( ) No

Nurse

( ) Yes ( ) No (X) Unk